[go: up one dir, main page]

WO2009129498A3 - Substance p and analogs thereof as a cancer immunogenic composition adjuvant - Google Patents

Substance p and analogs thereof as a cancer immunogenic composition adjuvant Download PDF

Info

Publication number
WO2009129498A3
WO2009129498A3 PCT/US2009/041022 US2009041022W WO2009129498A3 WO 2009129498 A3 WO2009129498 A3 WO 2009129498A3 US 2009041022 W US2009041022 W US 2009041022W WO 2009129498 A3 WO2009129498 A3 WO 2009129498A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
analogs
immunogenic composition
composition adjuvant
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/041022
Other languages
French (fr)
Other versions
WO2009129498A2 (en
Inventor
Michael Klaus Wilhelm
Hal N. Siegel
Adriana T. Larregina
Adrian Eduardo Morelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Immuneregen Biosciences Inc
Original Assignee
University of Pittsburgh
Immuneregen Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh, Immuneregen Biosciences Inc filed Critical University of Pittsburgh
Publication of WO2009129498A2 publication Critical patent/WO2009129498A2/en
Publication of WO2009129498A3 publication Critical patent/WO2009129498A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed herein are methods and compositions effective for treating, preventing, and ameliorating cancer that utilize Substance P or Substance P analogs and antigens. Also disclosed are methods for vaccinating a patient against cancer that utilize Substance P or Substance P analogs and antigens.
PCT/US2009/041022 2008-04-17 2009-04-17 Substance p and analogs thereof as a cancer immunogenic composition adjuvant Ceased WO2009129498A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4585608P 2008-04-17 2008-04-17
US61/045,856 2008-04-17

Publications (2)

Publication Number Publication Date
WO2009129498A2 WO2009129498A2 (en) 2009-10-22
WO2009129498A3 true WO2009129498A3 (en) 2009-12-23

Family

ID=41100681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041022 Ceased WO2009129498A2 (en) 2008-04-17 2009-04-17 Substance p and analogs thereof as a cancer immunogenic composition adjuvant

Country Status (1)

Country Link
WO (1) WO2009129498A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748170B2 (en) * 2008-07-25 2014-06-10 University of Pittsburgh—of the Commonwealth System of Higher Education Polypeptides derived from cyclin B1 and uses thereof
KR102225547B1 (en) * 2019-05-28 2021-03-10 주식회사 바이오솔루션 Cosmetic composition comprising substance P for whitening skin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024822A2 (en) * 1999-10-01 2001-04-12 Cistem Biotechnologies Gmbh Pharmaceutical composition comprising an antigen
WO2002010194A1 (en) * 2000-07-31 2002-02-07 Dabur Research Foundation Substance p analogs for the treatment of cancer
WO2003102023A1 (en) * 2002-05-29 2003-12-11 Immatics Biotechnologies Gmbh Tumour-associated peptides that bond to mhc molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024822A2 (en) * 1999-10-01 2001-04-12 Cistem Biotechnologies Gmbh Pharmaceutical composition comprising an antigen
WO2002010194A1 (en) * 2000-07-31 2002-02-07 Dabur Research Foundation Substance p analogs for the treatment of cancer
WO2003102023A1 (en) * 2002-05-29 2003-12-11 Immatics Biotechnologies Gmbh Tumour-associated peptides that bond to mhc molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAMBRECHT B N ET AL: "Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation.", EUROPEAN JOURNAL OF IMMUNOLOGY DEC 1999, vol. 29, no. 12, December 1999 (1999-12-01), pages 3815 - 3825, XP002548220, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
WO2009129498A2 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
EP4219566A3 (en) Recombinant rsv antigens
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2009156960A9 (en) Novel adjuvant compositions
MX2012000035A (en) Recombinant rsv antigens.
GB201101665D0 (en) Immunogenic compositions
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2011005595A3 (en) 2-5a analogs and their methods of use
IN2012DN02736A (en)
WO2008039974A3 (en) Cancer vaccines and vaccination methods
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2077830A4 (en) Methods, compositions, and formulations for the treatment of thyroid eye disease
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2011075822A8 (en) Immunogenic compositions and related methods
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
CA2763359C (en) New human rotavirus strains and vaccines
WO2008127296A3 (en) Methods and compositions for treating tularemia
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2009061374A3 (en) Deuterated fingolimod
WO2006091722A3 (en) Alkyl-glycoside enhanced vaccination
WO2010012045A8 (en) Influenza vaccines
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant
WO2011074006A3 (en) Vaccine composition
EA201290319A1 (en) APPLICATION OF L3 AND / OR L5 SOURCE AS A VACCINE OR DIAGNOSTIC MEANS FOR PARASITIC DISEASE
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
UA93901C2 (en) Vaccine against mycoplasma prrs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09733491

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09733491

Country of ref document: EP

Kind code of ref document: A2